Overdiagnosis in primary care: Framing the problem and finding solutions

BMJ (Online)

Volumn 362, Issue , 2018, Pages

  Kale, Minal S ^a   Korenstein, Deborah ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL OUTCOME; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; EVIDENCE BASED PRACTICE; HEALTH CARE SYSTEM; HUMAN; MORTALITY RATE; OVERDIAGNOSIS; POINT OF CARE TESTING; POPULATION RISK; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; HEALTH SERVICE; MASS SCREENING; PRIMARY HEALTH CARE; TRENDS;

HUMANS; MASS SCREENING; MEDICAL OVERUSE; PRIMARY HEALTH CARE;

EID: 85051571708     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.k2820     Document Type: Review

References (118)

1. WHO. The world health report 2008: primary health care now more than ever. WHO, 2008. http://www.who.int/whr/2008/en/
2. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13. 10.1093/jnci/djq099.pmid:20413742
3. Black WC. Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst 2000;92:1280-2. 10.1093/jnci/92.16.1280pmid:10944539
4. Carter SM, Rogers W, Heath I, Degeling C, Doust J, Barratt A. The challenge of overdiagnosis begins with its definition. BMJ 2015;350:h869. 10.1136/bmj.h869.pmid:25740625
5. Llor C. Reducing overdiagnosis in primary care is needed. Eur J Gen Pract 2017;23:215-6. 10.1080/13814788.2017.1365836.pmid:28914565
6. Morgan DJ, Brownlee S, Leppin AL, et al. Setting a research agenda for medical overuse. BMJ 2015;351:h4534. 10.1136/bmj.h4534.pmid:26306661
7. Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A. Effect of screening for type2 diabetes on risk of cardiovascular disease and mortality: A controlled trial among 139 075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia 2017;60:2192-9. 10.1007/s00125-017-4299-y.pmid:28831539
8. Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R. Screening for type2 diabetes mellitus: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015;162:765-76. 10.7326/M14-2221.pmid:25867111
9. Morris DH, Khunti K, Achana F, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type2 diabetes: A meta-analysis. Diabetologia 2013;56:1489-93. 10.1007/s00125-013-2902-4.pmid:23584433
10. National Institute for Health and Care Excellence. Type2 diabetes: prevention in people at high risk.2012. https://www.nice.org.uk/guidance/ph38/chapter/Recommendations
11. Pottie K, Jaramillo A, Lewin G, et al. Canadian Task Force on Preventive Health Care. Recommendations on screening for type2 diabetes in adults. CMAJ 2012;184:1687-96. 10.1503/cmaj.120732.pmid:23073674
12. Fox MS. On the diagnosis and treatment of breast cancer. JAMA 1979;241:489-94. 10.1001/jama.1979.03290310029009pmid:759664
13. Zwaan L, Singh H. The challenges in defining and measuring diagnostic error. Diagnosis (Berl) 2015;2:97-103. 10.1515/dx-2014-0069.pmid:26955512
14. Rodríguez-Gutiérrez R, Montori VM. Glycemic control for patients with type2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes 2016;9:504-12. 10.1161/CIRCOUTCOMES.116.002901.pmid:27553599
15. Winearls CG, Glassock RJ. Classification of chronic kidney disease in the elderly: pitfalls and errors. Nephron Clin Pract 2011;119(Suppl 1):c2-4. 10.1159/000328013.pmid:21832853
16. Moynihan R, Glassock R, Doust J. Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased. BMJ 2013;347:f4298. 10.1136/bmj.f4298.pmid:23900313
17. Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 2017;317:2515-23. 10.1001/jama.2017.7596.pmid:28655017
18. Van den Bruel A. The triumph of medicine: how overdiagnosis is turning healthy people into patients. Fam Pract 2015;32:127-8. 10.1093/fampra/cmv008.pmid:25805809
19. Topstad D, Dickinson JA. Thyroid cancer incidence in Canada: A national cancer registry analysis. CMAJ Open 2017;5:E612-6. 10.9778/cmajo.20160162.pmid:28807924
20. de Gelder R, Fracheboud J, Heijnsdijk EA, et al. Digital mammography screening: weighing reduced mortality against increased overdiagnosis. Prev Med 2011;53:134-40. 10.1016/j.ypmed.2011.06.009.pmid:21718717.
21. Depypere H, Desreux J, Pérez-López FR, et al. EMAS position statement: Individualized breast cancer screening versus population-based mammography screening programmes. Maturitas 2014;79:481-6. 10.1016/j.maturitas.2014.09.002.pmid:25277123
22. Puliti D, Duffy SW, Miccinesi G, et al. EUROSCREEN Working Group. Overdiagnosis in mammographic screening for breast cancer in Europe: A literature review. J Med Screen 2012;19(Suppl 1):42-56. 10.1258/jms.2012.012082.pmid:22972810
23. Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. 'The thing is not knowing': patients' perspectives on surveillance of an indeterminate pulmonary nodule. Health Expect 2015;18:355-65. 10.1111/hex.12036.pmid:23252477
24. Herzstein J, Ebell M. Improving quality by doing less: overtreatment. Am Fam Physician 2015;91:289-91.pmid:25822384
25. Rank B. Executive physicals-bad medicine on three counts. N Engl J Med 2008;359:1424-5. 10.1056/NEJMp0806270.pmid:18832242
26. Hughes DR, Bhargavan M, Sunshine JH. Imaging self-referral associated with higher costs and limited impact on duration of illness. Health Aff (Millwood) 2010;29:2244-51. 10.1377/hlthaff.2010.0413.pmid:21134926
27. Lord SJ, Staub LP, Bossuyt PM, Irwig LM. Target practice: choosing target conditions for test accuracy studies that are relevant to clinical practice. BMJ 2011;343:d4684. 10.1136/bmj.d4684.pmid:21903693
28. Prasad V, Rho J, Cifu A. The diagnosis and treatment of pulmonary embolism: A metaphor for medicine in the evidence-based medicine era. Arch Intern Med 2012;172:955-8. 10.1001/archinternmed.2012.195.pmid:22473672
29. Engelgau MM, Thompson TJ, Herman WH, et al. Comparison of fasting and2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997; 20:785-91. 10.2337/diacare.20.5.785pmid:9135943
30. Yudkin JS, Montori VM. The epidemic of pre-diabetes: The medicine and the politics. BMJ 2014;349:g4485. 10.1136/bmj.g4485.pmid:25028385
31. Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: Implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012;97:1067-72. 10.1210/jc.2011-1894.pmid:22238408
32. Alonso-Coello P, García-Franco AL, Guyatt G, Moynihan R. Drugs for pre-osteoporosis: prevention or disease mongering. BMJ 2008;336:126-9. 10.1136/bmj.39435.656250.AD.pmid:18 20 2066
33. Fuchs FD, Fuchs SC, Poli-de-Figueiredo CE, et al. Effectiveness of low-dose diuretics for blood pressure reduction to optimal values in prehypertension: A randomized clinical trial. J Hypertens 2018;36:933-8. 10.1097/HJH.0000000000001624.pmid:29227377
34. Wiener RS, Schwartz LM, Woloshin S. When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found. BMJ 2013;347:f3368. 10.1136/bmj.f3368.pmid:238 20021
35. Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 2010;7:754-73. 10.1016/j.jacr.2010.06.013.pmid: 20889105
36. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic. The increasing impact of overdiagnosis. N Engl J Med 2016;375:614-7. 10.1056/NEJMp1604412.pmid:27532827
37. Diamandis EP, Li M. The side effects of translational omics: overtesting, overdiagnosis, overtreatment. Clin Chem Lab Med 2016;54:389-96. 10.1515/cclm-2015-0762.pmid:26444364
38. Gates TJ. Screening for cancer: concepts and controversies. Am Fam Physician 2014;90:625-31.pmid:25368922
39. Barratt A. Overdiagnosis in mammography screening: A 45 year journey from shadowy idea to acknowledged reality. BMJ 2015;350:h867. 10.1136/bmj.h867.pmid:25736426
40. Marmot M, Altman DG, Cameron DA, et al. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: An independent review. Lancet 2012;380:1778-86. 10.1016/S0140-6736(12)61611-0.pmid:23117178
41. Welch HG, Fisher ES. Income and cancer overdiagnosis-when too much care is harmful. N Engl J Med 2017;376:2208-9. 10.1056/NEJMp1615069.pmid:28591536
42. Schwartz LM, Woloshin S, Fowler FJ Jr, , Welch HG. Enthusiasm for cancer screening in the United States. JAMA 2004;291:71-8. 10.1001/jama.291.1.71.pmid:14709578
43. Van den Bruel A, Jones C, Yang Y, Oke J, Hewitson P. People's willingness to accept overdetection in cancer screening: population survey. BMJ 2015;350:h980. 10.1136/bmj.h980.pmid:25736617
44. Lee TJ, Kim S, Cho HJ, Lee JH. The incidence of thyroid cancer is affected by the characteristics of a healthcare system. J Korean Med Sci 2012;27:1491-8. 10.3346/jkms.2012.27.12.1491.pmid:23255848
45. Batstra L, Frances A. Diagnostic inflation: causes and a suggested cure. J Nerv Ment Dis 2012; 200:474-9. 10.1097/NMD.0b013e318257c4a2.pmid:22652609
46. Golestaneh L, Cowan E. Hidden conflicts of interest in continuing medical education. Lancet 2017;390:2128-30. 10.1016/S0140-6736(17)32813-1.pmid:29143744
47. Jefferson AA, Pearson SD. Conflict of interest in seminal hepatitis C virus and cholesterol management guidelines. JAMA Intern Med 2017;177:352-7. 10.1001/jamainternmed.2016.8439.pmid:28114439
48. Moynihan R, Heath I, Henry D. Selling sickness: The pharmaceutical industry and disease mongering. BMJ 2002;324:886-91. 10.1136/bmj.324.7342.886 pmid:11950740
49. Mailankody S, Prasad V. Pharmaceutical marketing for rare diseases: regulating drug company promotion in an era of unprecedented advertisement. JAMA 2017;317:2479-80. 10.1001/jama.2017.5784.pmid:285 20871
50. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-2. 10.1136/bmj.312.7023.71.pmid:8555924
51. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S. Helping doctors and patients make sense of health statistics. Psychol Sci Public Interest 2007;8:53-96. 10.1111/j.1539-6053.2008.00033.x.pmid:26161749
52. Whiting PF, Davenport C, Jameson C, et al. How well do health professionals interpret diagnostic information. A systematic review. BMJ Open 2015;5:e008155. 10.1136/bmjopen-2015-008155.pmid:262 20870
53. Klein JG. Five pitfalls in decisions about diagnosis and prescribing. BMJ 2005;330:781-3. 10.1136/bmj.330.7494.781.pmid:15802723
54. Scott IA, Soon J, Elshaug AG, Lindner R. Countering cognitive biases in minimising low value care. Med J Aust 2017; 206:407-11. 10.5694/mja16.00999 pmid:28490292
55. Kohn MA, Carpenter CR, Newman TB. Understanding the direction of bias in studies of diagnostic test accuracy. Acad Emerg Med 2013; 20:1194-206. 10.1111/acem.12255.pmid:24238322
56. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification. JAMA 2007;298:1209-12. 10.1001/jama.298.10.1209.pmid:17848656
57. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-54. 10.1056/NEJMoa1301851.pmid:23863051
58. Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. Harms of breast cancer screening: systematic review to update the 2009 US Preventive Services Task Force Recommendation. Ann Intern Med 2016;164:256-67. 10.7326/M15-0970.pmid:26756737
59. Adhmed O, Moran D, Daly P, et al. PSA testing: whom, by whom and how often?Ir J Med Sci 2014;183:(suppl 5)S237-38. 10.1007/s11845-014-1168-2
60. Chen Y, Yang K, Marušic A, et al. RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. A reporting tool for practice guidelines in health care: The RIGHT statement. Ann Intern Med 2017;166:128-32. 10.7326/M16-1565.pmid:27893062
61. Jenniskens K, de Groot JAH, Reitsma JB, Moons KGM, Hooft L, Naaktgeboren CA. Overdiagnosis across medical disciplines: A scoping review. BMJ Open 2017;7:e018448. 10.1136/bmjopen-2017-018448.pmid:292847 20
62. Melzer D, Tavakoly B, Winder RE, et al. Much more medicine for the oldest old: Trends in UK electronic clinical records. Age Ageing 2015;44:46-53. 10.1093/ageing/afu113.pmid:25103030
63. Johansson M, Hansson A, Brodersen J. Estimating overdiagnosis in screening for abdominal aortic aneurysm: could a change in smoking habits and lowered aortic diameter tip the balance of screening towards harm?BMJ 2015;350:h825. 10.1136/bmj.h825.pmid:25736421
64. Brodersen J. How to conduct research on overdiagnosis. A keynote paper from the EGPRN May 2016, Tel Aviv. Eur J Gen Pract 2017;23:78-82. 10.1080/13814788.2017.1290795.pmid:28299948
65. McCaffery KJ, Jansen J, Scherer LD, et al. Walking the tightrope: communicating overdiagnosis in modern healthcare. BMJ 2016;352:i348. 10.1136/bmj.i348.pmid:26850726
66. Roksund G, Brodersen J, Johnson GE, Hjörleifsson S, Laudal M, Swensen E. Overdiagnosis-Norwegian general practitioners show the way. Tidsskr Nor Laegeforen 2016;136:1903-5. 10.4045/tidsskr.16.0572.pmid:27929558
67. Davies L, Hendrickson CD, Hanson GS. Experience of US patients who self-identify as having an overdiagnosed thyroid cancer: A qualitative analysis. JAMA Otolaryngol Head Neck Surg 2017;143:663-9. 10.1001/jamaoto.2016.4749.pmid:28278335
68. Doust J, Glasziou P. Is the problem that everything is a diagnosis?Aust Fam Physician 2013;42:856-9.pmid:24324985
69. de Ridder D, Geenen R, Kuijer R, van Middendorp H. Psychological adjustment to chronic disease. Lancet 2008;372:246-55. 10.1016/S0140-6736(08)61078-8.pmid:18640461
70. Schairer C, Brown LM, Chen BE, et al. Suicide after breast cancer: An international population-based study of 723,810 women. J Natl Cancer Inst 2006;98:1416-9. 10.1093/jnci/djj377.pmid:17018788
71. Turner J, Kelly B. Emotional dimensions of chronic disease. West J Med 2000;172:124-8. 10.1136/ewjm.172.2.124 pmid:10693376
72. King MT, Winters ZE, Olivotto IA, et al. Patient-reported outcomes in ductal carcinoma in situ: A systematic review. Eur J Cancer 2017;71:95-108. 10.1016/j.ejca.2016.09.035.pmid:27987454
73. van Luijt PA, Heijnsdijk EA, Fracheboud J, et al. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res 2016;18:47. 10.1186/s13058-016-0705-5.pmid:27160733.
74. Cotter AR, Vuong K, Mustelin L, et al. Do psychological harms result from being labelled with an unexpected diagnosis of abdominal aortic aneurysm or prostate cancer through screening. A systematic review. BMJ Open 2017;7:e017565. 10.1136/bmjopen-2017-017565.pmid:29237653
75. DeFrank JT, Barclay C, Sheridan S, et al. The psychological harms of screening: The evidence we have versus the evidence we need. J Gen Intern Med 2015;30:242-8. 10.1007/s11606-014-2996-5.pmid:25150033
76. Bergman AB, Stamm SJ. The morbidity of cardiac nondisease in schoolchildren. N Engl J Med 1967;276:1008-13. 10.1056/NEJM196705042761804.pmid:6022469
77. Coon ER, Quinonez RA, Moyer VA, Schroeder AR. Overdiagnosis: how our compulsion for diagnosis may be harming children. Pediatrics 2014;134:1013-23. 10.1542/peds.2014-1778.pmid:25287462
78. Graves JM, Fulton-Kehoe D, Jarvik JG, Franklin GM. Early imaging for acute low back pain: one-year health and disability outcomes among Washington State workers. Spine (Phila Pa 1976) 2012;37:1617-27. 10.1097/BRS.0b013e318251887b.pmid:22415000
79. Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA 2012;307:1513-6. 10.1001/jama.2012.362.pmid:22419800
80. Ong MS, Mandl KD. National expenditure for false-positive mammograms and breast cancer overdiagnoses estimated at $4 billion a year. Health Aff (Millwood) 2015;34:576-83. 10.1377/hlthaff.2014.1087.pmid:25847639
81. Organisation for Economic Co-operation and Development. Fiscal sustainability of health systems. OECD Publishing, 2015. http://www.oecd.org/publications/fiscal-sustainability-of-health-systems-9789264233386-en.htm
82. Chassin MR, Galvin RW. Institute of Medicine National Roundtable on Health Care Quality. The urgent need to improve health care quality. JAMA 1998;280:1000-5. 10.1001/jama.280.11.1000pmid:9749483
83. National Cancer Institute. NCI dictionary of cancer terms: overtreatment. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/overtreatment
84. Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM. Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med 2014;174:259-68. 10.1001/jamainternmed.2013.12963.pmid:24322626
85. Dictionary OL. Misdiagnosis: Oxford Living Dictionaries. c 2018. https://en.oxforddictionaries.com/definition/misdiagnosis
86. Schpero WL. Limiting low-value care by "choosing wisely". Virtual Mentor 2014;16:131-4. 10.1001/virtualmentor.2014.16.02.pfor2-1402.pmid:24553334
87. Schwartz AL, Landon BE, Elshaug AG, Chernew ME, McWilliams JM. Measuring low-value care in Medicare. JAMA Intern Med 2014;174:1067-76. 10.1001/jamainternmed.2014.1541.pmid:24819824
88. Valk MJ, Mosterd A, Broekhuizen BD, et al. Overdiagnosis of heart failure in primary care: A cross-sectional study. Br J Gen Pract 2016;66:e587-92. 10.3399/bjgp16X685705.pmid:27266859
89. Clark D. Between hope and acceptance: The medicalisation of dying. BMJ 2002;324:905-7. 10.1136/bmj.324.7342.905 pmid:11950744
90. Ebeling M. 'Get with the Program!': pharmaceutical marketing, symptom checklists and self-diagnosis. Soc Sci Med 2011;73:825-32. 10.1016/j.socscimed.2011.05.054.pmid:21835526
91. Mintzes B. Disease mongering in drug promotion: do governments have a regulatory role?PLoS Med 2006;3:e198. 10.1371/journal. pmed.0030198.pmid:16597181
92. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV.4th ed. American Psychiatric Association, 1994:866
93. Epperson CN, Steiner M, Hartlage SA, et al. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry 2012;169:465-75. 10.1176/appi.ajp.2012.11081302.pmid:22764360
94. Petersen M. Market place; drug maker is set to ship generic prozac. New York Times 2001 Aug 2
95. Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol 2018;218:68-74. 10.1016/j.ajog.2017.05.045.pmid:28571724
96. Layton JB, Kim Y, Alexander GC, Emery SL. Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. JAMA 2017;317:1159-66. 10.1001/jama.2016.21041.pmid:28324090
97. Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: A systematic review of methods. BMJ 2015;350:g7773. 10.1136/bmj.g7773.pmid:25569 206
98. Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med 2013;158:831-8. 10.7326/0003-4819-158-11-201306040-00008.pmid:23732716
99. Coldman A, Phillips N. Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program. CMAJ 2013;185:E492-8. 10.1503/cmaj.121791.pmid:23754101
100. Han SS, Ten Haaf K, Hazelton WD, et al. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. Int J Cancer 2017;140:2436-43. 10.1002/ijc.30602.pmid:28073150
101. Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Stage migration in clinically localized prostate cancer. Eur Urol 2000;38:74-8. 10.1159/0000 20255 pmid:10859445
102. Carter SM, Degeling C, Doust J, et al. A definition and ethical evaluation of overdiagnosis. J Med Ethics 2016. 10.1136/medethics-2015-102928
103. Doust J, Vandvik PO, Qaseem A, et al. Guidelines International Network (G-I-N) Preventing Overdiagnosis Working Group. Guidance for modifying the definition of diseases: A checklist. JAMA Intern Med 2017;177:10 20-5. 10.1001/jamainternmed.2017.1302.pmid:28505266
104. Heidenreich A, Abrahamsson PA, Artibani W, et al. European Association of Urology. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol 2013;64:347-54. 10.1016/j.eururo.2013.06.051.pmid:23856038
105. Moyer VA. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156:880-91, W312. 10.7326/0003-4819-156-12-201206190-00424.pmid:22711081
106. Siu AL. U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2016;164:279-96. 10.7326/M15-2886.pmid:26757170
107. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management.2011. https://www.nice.org.uk/guidance/cg127
108. Kung J, Miller RR, Mackowiak PA. Failure of clinical practice guidelines to meet Institute of Medicine standards: Two more decades of little, if any, progress. Arch Intern Med 2012;172:1628-33. 10.1001/2013. jamainternmed.56.pmid:23089902
109. Moynihan R, Nickel B, Hersch J, et al. Public opinions about overdiagnosis: A national community survey. PLoS One 2015;10:e0125165. 10.1371/journal.pone.0125165.pmid:25992887
110. Wegwarth O, Gigerenzer G. Less is more: Overdiagnosis and overtreatment: evaluation of what physicians tell their patients about screening harms. JAMA Intern Med 2013;173: 2086-7. 10.1001/jamainternmed.2013.10363.pmid:24145597.
111. Nagler RH, Franklin Fowler E, Gollust SE. Women's awareness of and responses to messages about breast cancer overdiagnosis and overtreatment: results from a 2016 national survey. Med Care 2017;55:879-85. 10.1097/MLR.0000000000000798.pmid:28857962
112. Park SH, Lee B, Lee S, et al. A qualitative study of women's views on overdiagnosis and screening for thyroid cancer in Korea. BMC Cancer 2015;15:858. 10.1186/s12885-015-1877-6.pmid:26546276
113. Hersch J, Barratt A, Jansen J, et al. Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: A randomised controlled trial. Lancet 2015;385:1642-52. 10.1016/S0140-6736(15)60123-4.pmid:25701273
114. Haugen BR, Alexander EK, Bible KC, et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133. 10.1089/thy.2015.00 20.pmid:26462967
115. Parker C, Gillessen S, Heidenreich A, Horwich A. ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):v69-77. 10.1093/annonc/mdv222.pmid:26 205393
116. Benson JR, Jatoi I, Toi M. Treatment of low-risk ductal carcinoma in situ: Is nothing better than something. Lancet Oncol 2016;17:e442-51. 10.1016/S1470-2045(16)30367-9.pmid:27733270
117. Kim C, Wright FC, Look Hong NJ, et al. Patient and provider experiences with active surveillance: A scoping review. PLoS One 2018;13:e019 2097. 10.1371/journal. pone.019 2097.pmid:29401514
118. Jang TL, Bekelman JE, Liu Y, et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 2010;170:440-50. 10.1001/archinternmed.2010.1.pmid: 20212180